Table 1.
Baseline characteristics of 87 patients with HCC treated with TACE.
| Characteristics | Value |
|---|---|
| Sex (F) | 16 (18) |
| Age (years) | 68 ± 9 (45–88) |
| BMI | 28 (17-42) |
| Clinical liver cirrhosis | 68 (78) |
| Viral hepatitis* | 13 (15) |
| Alcoholic fatty liver disease | 12 (14) |
| Alcoholic fatty liver disease + viral hepatitis† | 20 (23) |
| Non-alcoholic fatty liver disease | 6 (7) |
| Others† | 17 (19) |
| No clinical liver cirrhosis | 9 (10) |
| HCC diagnosed with biopsy, AFP + imaging, no information | 6, 2, 1 |
| No information on liver cirrhosis | 10 (12) |
| HCC diagnosed with biopsy, AFP + imaging, no information | 3, 4, 3 |
| BCLC (A (%)/B (%)/C (%)) | 29 (33)/49 (56)/9 (11) |
| Child Pugh (A (%)/B (%)) | 77 (88)/10 (12) |
| Systemic chemotherapy and/or radiation pre-TACE | 7 (8) |
| Surgical resection and/or ablation pre-TACE | 13 (15) |
| Number of tumors | 3.4 (1–50) |
| 1 | 36 (41) |
| 2 | 19 (22) |
| >2 | 31 (37) |
| Bilobar | 30 (35) |
| Largest tumor diameter (cm) | 6.2 (1.6–19) |
| Transplanted after TACE | 4 (5) |
| AFP‡ | 941 (2–14,480) |
Values are given as n (%), mean ± SD (range), or mean (range) unless otherwise indicated.
*Viral hepatitis B or C.
†
Others include: alcoholic fatty liver disease + with non-alcoholic fatty liver disease (n = 3); hemochromatosis (n = 1); porphyria (n = 2); hemochromatosis + alcohol fatty liver disease + viral hepatitis (n = 1); hemochromatosis + alcoholic fatty liver disease + non-alcoholic fatty liver disease (n = 1); and unclear etiology (n = 9).
‡
Only available in 81 patients.
AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; BMI, body mass index; HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization.